
CGON Stock Forecast & Price Target
CGON Analyst Ratings
Bulls say
CG Oncology is a promising late-stage clinical biopharmaceutical company with a potential best-in-class asset, cretostimogene grenadenorepvec, for the treatment of bladder cancer, with potential for significant market share in multiple indications. The company's strong pipeline, progress towards a BLA filing, and potential for multiple upcoming catalysts make it an exciting investment opportunity. Despite increasing spend, the company has a strong cash position to fund its operations through 2029, and a potentially lucrative peak revenue opportunity of $3.3 billion by 2034.
Bears say
CG Oncology is currently focusing on developing its late-stage product candidate, cretostimogene grenadenorepvec, for bladder cancer patients. While the company is conducting multiple trials and has a potential $1.2 billion peak sales opportunity, there are still questions surrounding the durability of the efficacy data, interpretation of stage reclassifications in the dataset, and tolerability differences between arms. Additionally, there is a clinical risk and potential challenges in achieving regulatory and commercial success. Overall, there are uncertainties that could impact the company's financial performance and make it a risky investment at this time.
This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares